|
- 积分
- 244
- 威望
- 244
- 包包
- 616
|
本帖最后由 细胞海洋 于 2016-1-23 09:51 编辑 $ {, I4 w3 R8 H2 F; f$ B2 ~& L
+ |/ }1 Q) |" D7 |6 M) a1 N0 p目录. Y8 y* c9 N' c8 R/ Y2 r+ b2 v
免疫治疗引领肿瘤治疗新模式 ...................................................................................................... 4$ R& k4 {: C; j
抗癌领域新突破 .................................................................................................................. 49 _5 J( P5 z9 P' e Z9 {0 ]
600 亿美元市场空间 ............................................................................................................ 4) I* C" d8 D* H* ^" A/ x
免疫检查点的突破——PD-1 ....................................................................................................... 5; L8 m. {% D/ x" G
PD-1 单抗——肿瘤免疫治疗的明星 .......................................................................................... 5
6 l4 L7 c4 i7 H: RPD-1 重磅产品频出 ............................................................................................................. 5, K) R- V) o% i1 V7 E4 i
在研PD-1 单抗全面开花 ....................................................................................................... 6
- j/ S: ~2 m9 P5 P2 ePD-1 临床试验数据——适应人群广泛，效果显著 .......................................................................... 78 p0 x# ~9 E ?; N3 C
PD-1 以优秀的临床表现快速斩获非小细胞肺癌适应症 .................................................................... 9
6 S4 F" e3 g P8 F3 BPD-1 联用——免疫鸡尾酒疗法引爆行业增长点 ............................................................................ 9) f% _0 @# z8 W5 c. g3 V# V
PD-1 市场前景广阔 ........................................................................................................... 102 {& u. d4 n& P1 D2 l* ?
免疫治疗热门靶点——PD-L1 ................................................................................................... 19
/ c7 Y* d4 [, A% N3 N7 tPD-L1 单抗免疫疗法原理 .................................................................................................... 195 k4 n* ?! |0 c# V6 c3 |! y- R
PD-L1 单抗在研情况 .......................................................................................................... 19
3 w* @3 L# e/ |& W. X) ePD-L1 联用——多靶点治疗新选择 ......................................................................................... 19
% O7 n. c7 \9 Q- D& e/ A3 L+ GPD-L1 未来市场 ............................................................................................................... 20
0 H4 F% [- ?2 u" }$ Y6 O5 N% m免疫治疗另一靶点——CTLA-4 .................................................................................................. 21
* U& {$ r9 X5 u& OCTLA-4 单抗免疫疗法原理 ................................................................................................... 21
1 Z8 Q5 ?" Y% L6 Y; L- r! gCTLA-4 单抗已上市产品 ..................................................................................................... 21+ Y+ ]: ^& i, a6 `4 L
CTLA-4 在研产品.............................................................................................................. 22
3 f4 h+ h0 n) V5 p. n q) ~6 SCTLA-4 的未来，联合用药是出路 .......................................................................................... 23' |% O8 D# O) A: [ v7 ^6 U1 E
相关公司简介 ........................................................................................................................ 240 h# t U9 D! A" K: l/ ~% j% O' Z& ~
君实生物 ........................................................................................................................ 24
7 m( F( l }& _% G" c恒瑞医药（确信买入评级） .................................................................................................. 25" P! `: N8 l+ g; X, S' F+ i% v
百时美施贵宝（BMS） ....................................................................................................... 26# _6 @9 C: A5 j7 X1 H3 r! E
默克（Merck） ................................................................................................................ 27
: D3 ~' w4 j! j- p0 y
- n) Y4 y( v0 t1 O1 i6 Y2 K2 n" g6 p
3 J! q( x0 H7 p8 j2 ][hide][/hide] |
附件: 你需要登录才可以下载或查看附件。没有帐号？注册
-
总评分: 威望 + 10
包包 + 20
查看全部评分
|
发表于 2016-1-23 09:08
发表于 2016-1-23 19:55
